Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2022 · 10-Q
Revenue$36.52M$36.52M−21.6% vs Q1 2021 Net Income-$15.39M-$15.39MN/M vs Q1 2021 EPS Diluted-$0.91-$0.91N/M vs Q1 2021 Operating Income$2,133,000−54.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Free Cash Flowderived$47,136,000+541.3% Margins · derivedOperating margin5.8%−4.3 pt vs Q1 2021
Net margin-42.1%−81.0 pt vs Q1 2021
ended Mar 31, 2022 · filed May 9, 2022 · 39 d after period end